Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECT: FOLFOX vs CarboP-pacliT in Esophageal Cancer
NCT02359968Phase 2Completed
- Sponsor
- Centre Oscar Lambret
- Start
- Feb 2015
- Primary completion
- Jan 2021
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of fluorouracil, oxaliplatin, folinic acid, carboplatin, paclitaxel in esophageal cancer, gastroesophageal junction cancer, sponsored by Centre Oscar Lambret. Started Feb 2015; status: completed.
02
Drugs
fluorouraciloxaliplatinfolinic acidcarboplatinpaclitaxel
03
Conditions
esophageal cancergastroesophageal junction cancer
Beyond the preview
Go deeper on NCT02359968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02359968.